{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:16:04Z","timestamp":1794024964315,"version":"4.8.0"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03456-w","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T20:53:11Z","timestamp":1781038391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Process Development of Site-Specific Antibody\u2013Drug Conjugates"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-5659","authenticated-orcid":false,"given":"Brian","family":"O\u2019Mara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7027-0183","authenticated-orcid":false,"given":"Shantanu","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"3456_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925\u201332. https:\/\/doi.org\/10.1038\/nbt.1480.","journal-title":"Nat Biotechnol"},{"key":"3456_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis N, Banerji U. Antibody-drug conjugates\u2014an emerging class of cancer treatment. Br J Cancer. 2016;114:362\u20137. https:\/\/doi.org\/10.1038\/bjc.2015.435.","journal-title":"Br J Cancer"},{"key":"3456_CR3","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736\u201342. https:\/\/doi.org\/10.1038\/bjc.2017.367.","journal-title":"Br J Cancer"},{"key":"3456_CR4","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","volume":"32","author":"N Jain","year":"2015","unstructured":"Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res. 2015;32:3526\u201340. https:\/\/doi.org\/10.1007\/s11095-015-1657-7.","journal-title":"Pharm Res"},{"key":"3456_CR5","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.1039\/C4OB01550A","volume":"12","author":"FF Schumacher","year":"2014","unstructured":"Schumacher FF, Nunes JPM, Maruani A, Chudasama V, Smith MEB, Chester KA, et al. Next generation maleimides enable the controlled assembly of antibody\u2013drug conjugates via native disulfide bond bridging. Org Biomol Chem. 2014;12:7261\u20139. https:\/\/doi.org\/10.1039\/C4OB01550A.","journal-title":"Org Biomol Chem"},{"key":"3456_CR6","unstructured":"Bones J, Broster K, Bailey AO, D\u2019Silva K, Moore RE, Niederkofler E, et al. Antibody\u2013drug conjugates: perspectives and characterization.\u00a02018.\u00a0https:\/\/www.ChromatographyonlineCom\/View\/Antibody-Drug-Conjugates-Perspectives-and-Characterization. Accessed\u00a0Mar 2026."},{"key":"3456_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/antib9010002","author":"D Leung","year":"2020","unstructured":"Leung D, Wurst JM, Liu T, Martinez RM, Datta-Mannan A, Feng Y. Antibody conjugates-recent advances and future innovations. Antibodies. 2020. https:\/\/doi.org\/10.3390\/antib9010002.","journal-title":"Antibodies"},{"key":"3456_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4161\/mabs.27436","volume":"6","author":"A Beck","year":"2014","unstructured":"Beck A, Reichert JM. Antibody-drug conjugates. MAbs. 2014;6:15\u20137. https:\/\/doi.org\/10.4161\/mabs.27436.","journal-title":"MAbs"},{"key":"3456_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1208\/s12249-017-0943-6","volume":"19","author":"HH Gong","year":"2018","unstructured":"Gong HH, Ihle N, Jones MT, Kelly K, Kott L, Raglione T, et al. Control strategy for small molecule impurities in antibody-drug conjugates. AAPS PharmSciTech. 2018;19:971\u20137. https:\/\/doi.org\/10.1208\/s12249-017-0943-6.","journal-title":"AAPS PharmSciTech"},{"key":"3456_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020447","volume":"16","author":"V Metrangolo","year":"2024","unstructured":"Metrangolo V, Engelholm LH. Antibody\u2013drug conjugates: the dynamic evolution from conventional to next-generation constructs. Cancers (Basel). 2024;16:447. https:\/\/doi.org\/10.3390\/cancers16020447.","journal-title":"Cancers (Basel)"},{"key":"3456_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206246","volume":"13","author":"J Ou","year":"2018","unstructured":"Ou J, Si Y, Goh K, Yasui N, Guo Y, Song J, et al. Bioprocess development of antibody-drug conjugate production for cancer treatment. PLoS One. 2018;13:e0206246. https:\/\/doi.org\/10.1371\/journal.pone.0206246.","journal-title":"PLoS One"},{"key":"3456_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1021\/acs.oprd.6b00067","volume":"20","author":"DY Jackson","year":"2016","unstructured":"Jackson DY. Processes for constructing homogeneous antibody drug conjugates. Org Process Res Dev. 2016;20:852\u201366. https:\/\/doi.org\/10.1021\/acs.oprd.6b00067.","journal-title":"Org Process Res Dev"},{"key":"3456_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/bc5004982","volume":"26","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Bertozzi CR. Site-specific antibody\u2013drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 2015;26:176\u201392. https:\/\/doi.org\/10.1021\/bc5004982.","journal-title":"Bioconjug Chem"},{"key":"3456_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1073\/pnas.1321237111","volume":"111","author":"F Tian","year":"2014","unstructured":"Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al. A general approach to site-specific antibody drug conjugates. Proceedings of the National Academy of Sciences. 2014;111:1766\u201371. https:\/\/doi.org\/10.1073\/pnas.1321237111.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"3456_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1684749","author":"G Roy","year":"2020","unstructured":"Roy G, Reier J, Garcia A, Martin T, Rice M, Wang J, et al. Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences. MAbs. 2020. https:\/\/doi.org\/10.1080\/19420862.2019.1684749.","journal-title":"MAbs"},{"key":"3456_CR16","doi-asserted-by":"publisher","first-page":"16101","DOI":"10.1073\/pnas.1211023109","volume":"109","author":"JY Axup","year":"2012","unstructured":"Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proceedings of the National Academy of Sciences. 2012;109:16101\u20136. https:\/\/doi.org\/10.1073\/pnas.1211023109.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"3456_CR17","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/19420862.2019.1624127","volume":"11","author":"M Cao","year":"2019","unstructured":"Cao M, De Mel N, Jiao Y, Howard J, Parthemore C, Korman S, et al. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis. MAbs. 2019;11:1064\u201376. https:\/\/doi.org\/10.1080\/19420862.2019.1624127.","journal-title":"MAbs"},{"key":"3456_CR18","doi-asserted-by":"publisher","DOI":"10.2991\/chi.k.210305.001","volume":"3","author":"R Assi","year":"2021","unstructured":"Assi R, Masri N, Dalle IA, El-Cheikh J, Ghanem H, Bazarbachi A. Polatuzumab Vedotin: current role and future applications in the treatment of patients with diffuse large B-Cell lymphoma. Clin Hematol Int. 2021;3:21. https:\/\/doi.org\/10.2991\/chi.k.210305.001.","journal-title":"Clin Hematol Int"},{"key":"3456_CR19","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1039\/D1SC05243H","volume":"13","author":"N Zacharias","year":"2022","unstructured":"Zacharias N, Podust VN, Kajihara KK, Leipold D, Del Rosario G, Thayer D, et al. A homogeneous high-DAR antibody\u2013drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides. Chem Sci. 2022;13:3147\u201360. https:\/\/doi.org\/10.1039\/D1SC05243H.","journal-title":"Chem Sci"},{"key":"3456_CR20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/D0CS00310G","volume":"50","author":"SJ Walsh","year":"2021","unstructured":"Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, et al. Site-selective modification strategies in antibody\u2013drug conjugates. Chem Soc Rev. 2021;50:1305\u201353. https:\/\/doi.org\/10.1039\/D0CS00310G.","journal-title":"Chem Soc Rev"},{"key":"3456_CR21","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1535-7163.MCT-23-0927","volume":"23","author":"LK Skidmore","year":"2024","unstructured":"Skidmore LK, Mills D, Kim JY, Knudsen NA, Nelson JD, Pal M, et al. Preclinical characterization of ARX517, a site-specific stable PSMA-targeted antibody-drug conjugate for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther. 2024;23:1842\u201353. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0927.","journal-title":"Mol Cancer Ther"},{"key":"3456_CR22","doi-asserted-by":"publisher","unstructured":"Yu W, Ramprasad M, Pal M, Chen C, Paruchuri S, Skidmore L, et al. Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in Late-stage clinical development 2023. https:\/\/doi.org\/10.1101\/2023.03.27.534450.","DOI":"10.1101\/2023.03.27.534450"},{"key":"3456_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1021\/acs.bioconjchem.4c00013","volume":"35","author":"A Sadiki","year":"2024","unstructured":"Sadiki A, Liu S, Vaidya SR, Kercher EM, Lang RT, McIsaac J, et al. Site-specific conjugation of native antibody: transglutaminase-mediated modification of a conserved glutamine while maintaining the primary sequence and core Fc glycan via trimming with an endoglycosidase. Bioconjug Chem. 2024;35:465\u201371. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00013.","journal-title":"Bioconjug Chem"},{"key":"3456_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2078466","author":"MA Wijdeven","year":"2022","unstructured":"Wijdeven MA, van Geel R, Hoogenboom JH, Verkade JMM, Janssen BMG, Hurkmans I, et al. Enzymatic glycan remodeling\u2013metal free click (GlycoConnect\u2122) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering. MAbs. 2022. https:\/\/doi.org\/10.1080\/19420862.2022.2078466.","journal-title":"MAbs"},{"key":"3456_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2498162","author":"M Wen","year":"2025","unstructured":"Wen M, Yu A, Park Y, Calarese D, Gerber H-P, Yin G. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. MAbs. 2025. https:\/\/doi.org\/10.1080\/19420862.2025.2498162.","journal-title":"MAbs"},{"key":"3456_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/abt\/tbaa027","volume":"3","author":"A Sadiki","year":"2020","unstructured":"Sadiki A, Vaidya SR, Abdollahi M, Bhardwaj G, Dolan ME, Turna H, et al. Site-specific conjugation of native antibody. Antibody Ther. 2020;3:271\u201384. https:\/\/doi.org\/10.1093\/abt\/tbaa027.","journal-title":"Antibody Ther"},{"key":"3456_CR27","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","volume":"26","author":"R van Geel","year":"2015","unstructured":"van Geel R, Wijdeven MA, Heesbeen R, Verkade JMM, Wasiel AA, van Berkel SS, et al. Chemoenzymatic conjugation of toxic payloads to the globally conserved N-Glycan of native mAbs provides homogeneous and highly efficacious antibody\u2013drug conjugates. Bioconjug Chem. 2015;26:2233\u201342. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00224.","journal-title":"Bioconjug Chem"},{"key":"3456_CR28","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q5A(R2): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.\u00a02024.\u00a0https:\/\/www.FdaGov\/Media\/163115\/Download. Accessed Mar 2026."},{"key":"3456_CR29","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological\/Biological Products.\u00a01996.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q5c-Quality-Biotechnological-Products-Stability-Testing-Biotechnologicalbiological-Products. Accessed Mar 2026."},{"key":"3456_CR30","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q5E: Comparability of Biotechnological\/Biological Products Subject to Changes in Their Manufacturing Process.\u00a02005.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q5e-Comparability-Biotechnologicalbiological-Products-Subject-Changes-Their-Manufacturing-Process. Accessed Mar 2026."},{"key":"3456_CR31","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.\u00a02000.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q6a-Specifications-Test-Procedures-and-Acceptance-Criteria-New-Drug-Substances-and-New-Drug-Products. Accessed Mar 2026."},{"key":"3456_CR32","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products.\u00a01999.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q6b-Specifications-Test-Procedures-and-Acceptance-Criteria-Biotechnologicalbiological-Products. Accessed Mar 2026."},{"key":"3456_CR33","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q8(R2): Pharmaceutical Development.\u00a02009.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q8r2-Pharmaceutical-Development. Accessed Mar 2026."},{"key":"3456_CR34","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q9(R1): Quality risk management.\u00a02023.\u00a0https:\/\/Www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q9r1-Quality-Risk-Management. Accessed Mar 2026."},{"key":"3456_CR35","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q10: Pharmaceutical quality system.\u00a02009.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q10-Pharmaceutical-Quality-System. Accessed Mar 2026."},{"key":"3456_CR36","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q11: Development and manufacture of drug substances (chemical entities and biotechnological\/biological entities).\u00a02012.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q11-Development-and-Manufacture-Drug-Substances. Accessed Mar 2026."},{"key":"3456_CR37","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management.\u00a02021.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q12-Technical-and-Regulatory-Considerations-Pharmaceutical-Product-Lifecycle-Management-Guidance. Accessed Mar 2026."},{"key":"3456_CR38","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q13: Continuous manufacturing of drug substances and drug products.\u00a02023.\u00a0https:\/\/www.FdaGov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Q13-Continuous-Manufacturing-Drug-Substances-and-Drug-Products. Accessed Mar 2026."},{"key":"3456_CR39","unstructured":"International Council of Harmonization (ICH). Q3A (R2): Impurities in New Drug Substances.\u00a02006.\u00a0https:\/\/www.DatabaseIchOrg\/Sites\/Default\/Files\/Q3A%28R2%29%20GuidelinePdf. Accessed Mar 2026."},{"key":"3456_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/abt\/tbaf010","volume":"8","author":"Q Fan","year":"2025","unstructured":"Fan Q, Chen H, Wei G, Wei D, Wang Z, Zhang L, et al. A review of conjugation technologies for antibody drug conjugates. Antib Ther. 2025;8:157\u201370. https:\/\/doi.org\/10.1093\/abt\/tbaf010.","journal-title":"Antib Ther"},{"key":"3456_CR41","doi-asserted-by":"publisher","first-page":"8558","DOI":"10.1021\/acs.analchem.9b01808","volume":"91","author":"K Li","year":"2019","unstructured":"Li K, Lin ZJ, Shi H, Ma Y. Characterization of positional isomers of interchain cysteine linked antibody\u2212drug conjugates by high-resolution mass spectrometry. Anal Chem. 2019;91:8558\u201363. https:\/\/doi.org\/10.1021\/acs.analchem.9b01808.","journal-title":"Anal Chem"},{"key":"3456_CR42","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1021\/acs.analchem.6b00822","volume":"88","author":"A Kita","year":"2016","unstructured":"Kita A, Ponniah G, Nowak C, Liu H. Characterization of cysteinylation and trisulfide bonds in a recombinant monoclonal antibody. Anal Chem. 2016;88:5430\u20137. https:\/\/doi.org\/10.1021\/acs.analchem.6b00822.","journal-title":"Anal Chem"},{"key":"3456_CR43","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1021\/bc050201y","volume":"16","author":"MMC Sun","year":"2005","unstructured":"Sun MMC, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, et al. Reduction\u2212Alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem. 2005;16:1282\u201390. https:\/\/doi.org\/10.1021\/bc050201y.","journal-title":"Bioconjug Chem"},{"key":"3456_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0.","journal-title":"Protein Cell"},{"key":"3456_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/19420862.2017.1412025","volume":"10","author":"A Wagh","year":"2018","unstructured":"Wagh A, Song H, Zeng M, Tao L, Das TK. Challenges and new frontiers in analytical characterization of antibody-drug conjugates. MAbs. 2018;10:222\u201343. https:\/\/doi.org\/10.1080\/19420862.2017.1412025.","journal-title":"MAbs"},{"key":"3456_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","volume":"3","author":"A Wakankar","year":"2011","unstructured":"Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011;3:161\u201372. https:\/\/doi.org\/10.4161\/mabs.3.2.14960.","journal-title":"MAbs"},{"key":"3456_CR47","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1021\/acs.analchem.5b00788","volume":"87","author":"A Dyachenko","year":"2015","unstructured":"Dyachenko A, Wang G, Belov M, Makarov A, de Jong RN, van den Bremer ETJ, et al. Tandem native mass-spectrometry on antibody\u2013drug conjugates and submillion Da antibody\u2013antigen protein assemblies on an Orbitrap EMR equipped with a high-mass quadrupole mass selector. Anal Chem. 2015;87:6095\u2013102. https:\/\/doi.org\/10.1021\/acs.analchem.5b00788.","journal-title":"Anal Chem"},{"key":"3456_CR48","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nbt.2968","volume":"32","author":"RP Lyon","year":"2014","unstructured":"Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson ME, et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol. 2014;32:1059\u201362. https:\/\/doi.org\/10.1038\/nbt.2968.","journal-title":"Nat Biotechnol"},{"key":"3456_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nmeth1016","volume":"4","author":"W Liu","year":"2007","unstructured":"Liu W, Brock A, Chen S, Chen S, Schultz PG. Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods. 2007;4:239\u201344. https:\/\/doi.org\/10.1038\/nmeth1016.","journal-title":"Nat Methods"},{"key":"3456_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3523","author":"JP Welsh","year":"2025","unstructured":"Welsh JP, Altern SH, Lyall JY, Burgess S, Rauscher MA, Lenhoff AM, et al. Coupling high\u2010throughput and modeling approaches to streamline early\u2010stage process development for biologics. Biotechnol Prog. 2025. https:\/\/doi.org\/10.1002\/btpr.3523.","journal-title":"Biotechnol Prog"},{"key":"3456_CR51","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1007\/s11095-015-1704-4","volume":"32","author":"SK Singh","year":"2015","unstructured":"Singh SK, Luisi DL, Pak RH. Antibody-drug conjugates: design, formulation and physicochemical stability. Pharm Res. 2015;32:3541\u201371. https:\/\/doi.org\/10.1007\/s11095-015-1704-4.","journal-title":"Pharm Res"},{"key":"3456_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/antib7010004","volume":"7","author":"G Falck","year":"2018","unstructured":"Falck G, M\u00fcller K. Enzyme-based labeling strategies for antibody\u2013drug conjugates and antibody mimetics. Antibodies Basel. 2018;7:4. https:\/\/doi.org\/10.3390\/antib7010004.","journal-title":"Antibodies Basel"},{"key":"3456_CR53","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.1002\/anie.201402606","volume":"53","author":"X Li","year":"2014","unstructured":"Li X, Fang T, Boons G. Preparation of well\u2010defined antibody\u2013drug conjugates through glycan remodeling and strain\u2010promoted azide\u2013alkyne cycloadditions. Angew Chem Int Ed Engl. 2014;53:7179\u201382. https:\/\/doi.org\/10.1002\/anie.201402606.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3456_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/antib12040071","volume":"12","author":"Q Yang","year":"2023","unstructured":"Yang Q, Chen H, Ou C, Zheng Z, Zhang X, Liu Y, et al. Evaluation of two chemoenzymatic glycan remodeling approaches to generate site-specific antibody\u2013drug conjugates. Antibodies. 2023;12:71. https:\/\/doi.org\/10.3390\/antib12040071.","journal-title":"Antibodies"},{"key":"3456_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrp.2023.101544","volume":"4","author":"T Nittoli","year":"2023","unstructured":"Nittoli T, Degrado SJ, Afsari HS, Anand P, Bos J, Choi S, et al. Site-specific antibody conjugations using bacterial transglutaminase and the Diels-Alder cycloaddition reaction. Cell Rep Phys Sci. 2023;4:101544. https:\/\/doi.org\/10.1016\/j.xcrp.2023.101544.","journal-title":"Cell Rep Phys Sci"},{"key":"3456_CR56","unstructured":"Han A, Olson W, D\u2019Souza C. Optimized transglutaminase site-specific antibody conjugation. US11786603B2, 2017."},{"key":"3456_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-1-4939-9929-3_9","volume-title":"Antibody conjugations via glycosyl remodeling","author":"H Toftevall","year":"2020","unstructured":"Toftevall H, Nyhl\u00e9n H, Olsson F, Sj\u00f6gren J. Antibody conjugations via glycosyl remodeling. 2020. p. 131\u201345. https:\/\/doi.org\/10.1007\/978-1-4939-9929-3_9."},{"key":"3456_CR58","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.4161\/mabs.29889","volume":"6","author":"Z Zhu","year":"2014","unstructured":"Zhu Z, Ramakrishnan B, Li J, Wang Y, Feng Y, Prabakaran P, et al. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs. 2014;6:1190\u2013200. https:\/\/doi.org\/10.4161\/mabs.29889.","journal-title":"MAbs"},{"key":"3456_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2923","author":"TJ Gates","year":"2020","unstructured":"Gates TJ, Lyu YF, Fang X, Liao X. Clearance of solvents and small molecule impurities in antibody drug conjugates via ultrafiltration and diafiltration operation. Biotechnol Prog. 2020. https:\/\/doi.org\/10.1002\/btpr.2923.","journal-title":"Biotechnol Prog"},{"key":"3456_CR60","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1021\/acs.bioconjchem.5c00599","volume":"37","author":"S Metya","year":"2026","unstructured":"Metya S, Prakash P, Rathore AS. Continuous processing for manufacturing of antibody-drug conjugates (ADCs). Bioconjug Chem. 2026;37:395\u2013405. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5c00599.","journal-title":"Bioconjug Chem"},{"key":"3456_CR61","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1208\/s12248-017-0083-7","volume":"19","author":"LN Tumey","year":"2017","unstructured":"Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, et al. Site selection: a case study in the identification of optimal cysteine engineered antibody drug conjugates. AAPS J. 2017;19:1123\u201335. https:\/\/doi.org\/10.1208\/s12248-017-0083-7.","journal-title":"AAPS J"},{"key":"3456_CR62","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1002\/anie.201712370","volume":"57","author":"B Oller\u2010Salvia","year":"2018","unstructured":"Oller\u2010Salvia B, Kym G, Chin JW. Rapid and efficient generation of stable antibody\u2013drug conjugates via an encoded cyclopropene and an inverse\u2010electron\u2010demand Diels\u2013Alder reaction. Angew Chem Int Ed Engl. 2018;57:2831\u20134. https:\/\/doi.org\/10.1002\/anie.201712370.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3456_CR63","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","volume":"16","author":"LX Yu","year":"2014","unstructured":"Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding Pharmaceutical Quality by Design. AAPS J. 2014;16:771\u201383. https:\/\/doi.org\/10.1208\/s12248-014-9598-3.","journal-title":"AAPS J"},{"key":"3456_CR64","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/bit.25561","volume":"112","author":"S Herzer","year":"2015","unstructured":"Herzer S, Bhangale A, Barker G, Chowdhary I, Conover M, O\u2019Mara BW, et al. Development and scale\u2010up of the recovery and purification of a domain antibody Fc fusion protein\u2010comparison of a two and three\u2010step approach. Biotechnol Bioeng. 2015;112:1417\u201328. https:\/\/doi.org\/10.1002\/bit.25561.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR65","volume-title":"Fundamentals of preparative and nonlinear chromatography","author":"G Guiochon","year":"2006","unstructured":"Guiochon G, Shirazi DG, Felinger A, Katti AM. Fundamentals of preparative and nonlinear chromatography. Academic Press; 2006."},{"key":"3456_CR66","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1021\/acs.iecr.8b04717","volume":"58","author":"O Yang","year":"2019","unstructured":"Yang O, Prabhu S, Ierapetritou M. Comparison between batch and continuous monoclonal antibody production and economic analysis. Ind Eng Chem Res. 2019;58:5851\u201363. https:\/\/doi.org\/10.1021\/acs.iecr.8b04717.","journal-title":"Ind Eng Chem Res"},{"key":"3456_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81366-6","volume":"11","author":"Y Imura","year":"2021","unstructured":"Imura Y, Tagawa T, Miyamoto Y, Nonoyama S, Sumichika H, Fujino Y, et al. Washing with alkaline solutions in Protein A purification improves physicochemical properties of monoclonal antibodies. Sci Rep. 2021;11:1827. https:\/\/doi.org\/10.1038\/s41598-021-81366-6.","journal-title":"Sci Rep"},{"key":"3456_CR68","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4161\/mabs.12303","volume":"2","author":"M Urmann","year":"2010","unstructured":"Urmann M, Graalfs H, Joehnck M, Jacob LR, Frech C. Cation-exchange chromatography of monoclonal antibodies: characterisation of a novel stationary phase designed for production-scale purification. MAbs. 2010;2:395\u2013404. https:\/\/doi.org\/10.4161\/mabs.12303.","journal-title":"MAbs"},{"key":"3456_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.70073","author":"L Lemire","year":"2026","unstructured":"Lemire L, Reyes S, Durocher Y, Voyer R, Henry O, Pham PL. Scale\u2010up of a monoclonal antibody CHO fed\u2010batch production in stirred tank bioreactors: effect of hydrodynamic conditions and feeding regimen. Biotechnol Prog. 2026. https:\/\/doi.org\/10.1002\/btpr.70073.","journal-title":"Biotechnol Prog"},{"key":"3456_CR70","doi-asserted-by":"publisher","first-page":"13613","DOI":"10.1039\/D1SC02973H","volume":"12","author":"MS Kang","year":"2021","unstructured":"Kang MS, Kong TWS, Khoo JYX, Loh T-P. Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody\u2013drug conjugates. Chem Sci. 2021;12:13613\u201347. https:\/\/doi.org\/10.1039\/D1SC02973H.","journal-title":"Chem Sci"},{"key":"3456_CR71","unstructured":"Scanlan C, Zhao J, Rogers M, Waghmare R, Xu S, Cross S, et al. Antibody-drug conjugates: manufacturing challenges and trends. ADC Review 2017."},{"key":"3456_CR72","unstructured":"World ADC Conference. Manufacturing and CMC perspectives. Manufacturing and CMC perspectives, 2022."},{"key":"3456_CR73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jbiotec.2019.08.013","volume":"305","author":"T Cui","year":"2019","unstructured":"Cui T, Chi B, Heidbrink Thompson J, Kasali T, Sellick C, Turner R. Cathepsin D: removal strategy on Protein A chromatography, near real time monitoring and characterisation during monoclonal antibody production. J Biotechnol. 2019;305:51\u201360. https:\/\/doi.org\/10.1016\/j.jbiotec.2019.08.013.","journal-title":"J Biotechnol"},{"key":"3456_CR74","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1021\/bc4000299","volume":"24","author":"K Cumnock","year":"2013","unstructured":"Cumnock K, Tully T, Cornell C, Hutchinson M, Gorrell J, Skidmore K, et al. Trisulfide modification impacts the reduction step in antibody\u2013drug conjugation process. Bioconjug Chem. 2013;24:1154\u201360. https:\/\/doi.org\/10.1021\/bc4000299.","journal-title":"Bioconjug Chem"},{"key":"3456_CR75","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2232486","author":"S Zhang","year":"2023","unstructured":"Zhang S, Riccardi C, Carlson D, Kamen D, Graham KS, Shameem M, et al. Prediction of long-term polysorbate degradation according to short-term degradation kinetics. MAbs. 2023. https:\/\/doi.org\/10.1080\/19420862.2023.2232486.","journal-title":"MAbs"},{"key":"3456_CR76","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/bit.25628","volume":"112","author":"DG Bracewell","year":"2015","unstructured":"Bracewell DG, Francis R, Smales CM. The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk\u2010based management for their control. Biotechnol Bioeng. 2015;112:1727\u201337. https:\/\/doi.org\/10.1002\/bit.25628.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2026.106893","volume":"240","author":"C Xuan","year":"2026","unstructured":"Xuan C, Xu Y, Cui X, Ma T, Lv F. Removal of polysorbates degradation-related impurities by depth filter screening: A case study. Protein Expr Purif. 2026;240:106893. https:\/\/doi.org\/10.1016\/j.pep.2026.106893.","journal-title":"Protein Expr Purif"},{"key":"3456_CR78","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.chroma.2016.11.019","volume":"1479","author":"S Ghose","year":"2017","unstructured":"Ghose S, Rajshekaran R, Labanca M, Conley L. Modeling on-column reduction of trisulfide bonds in monoclonal antibodies during Protein A chromatography. J Chromatogr A. 2017;1479:81\u20136. https:\/\/doi.org\/10.1016\/j.chroma.2016.11.019.","journal-title":"J Chromatogr A"},{"key":"3456_CR79","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1002\/bit.27769","volume":"118","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang M, Castan A, Hjalmarsson H, Chotteau V. Probabilistic model by Bayesian network for the prediction of antibody glycosylation in perfusion and fed\u2010batch cell cultures. Biotechnol Bioeng. 2021;118:3447\u201359. https:\/\/doi.org\/10.1002\/bit.27769.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR80","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.drudis.2016.04.004","volume":"21","author":"R-C Huang","year":"2016","unstructured":"Huang R-C, Chen G. Characterization of antibody\u2013drug conjugates by mass spectrometry: Advances and future trends. Drug Discov Today. 2016;21:850\u20135. https:\/\/doi.org\/10.1016\/j.drudis.2016.04.004.","journal-title":"Drug Discov Today"},{"key":"3456_CR81","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00253-024-13008-6","volume":"108","author":"S-L Geng","year":"2024","unstructured":"Geng S-L, Zhao X-J, Zhang X, Zhang J-H, Mi C-L, Wang T-Y. Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells. Appl Microbiol Biotechnol. 2024;108:182. https:\/\/doi.org\/10.1007\/s00253-024-13008-6.","journal-title":"Appl Microbiol Biotechnol"},{"key":"3456_CR82","doi-asserted-by":"publisher","first-page":"20564","DOI":"10.1021\/acsomega.9b02419","volume":"4","author":"Y Matsuda","year":"2019","unstructured":"Matsuda Y, Clancy C, Tawfiq Z, Robles V, Mendelsohn BA. Good manufacturing practice strategy for antibody-drug conjugate synthesis using site-specific chemical conjugation: First-generation AJICAP. ACS Omega. 2019;4:20564\u201370. https:\/\/doi.org\/10.1021\/acsomega.9b02419.","journal-title":"ACS Omega"},{"key":"3456_CR83","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2122957","author":"ZK Glover","year":"2022","unstructured":"Glover ZK, Wecksler A, Aryal B, Mehta S, Pegues M, Chan W, et al. Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species. MAbs. 2022. https:\/\/doi.org\/10.1080\/19420862.2022.2122957.","journal-title":"MAbs"},{"key":"3456_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3323","author":"B O\u2019Mara","year":"2023","unstructured":"O\u2019Mara B, Singh NK, Menendez A, Tipton B, Vail A, Voloshin A, et al. Single\u2010stage chromatographic clarification of Chinese Hamster Ovary cell harvest reduces cost of protein production. Biotechnol Prog. 2023. https:\/\/doi.org\/10.1002\/btpr.3323.","journal-title":"Biotechnol Prog"},{"key":"3456_CR85","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/bit.26964","volume":"116","author":"B O\u2019Mara","year":"2019","unstructured":"O\u2019Mara B, Gao Z, Kuruganti M, Mallett R, Nayar G, Smith L, et al. Impact of depth filtration on disulfide bond reduction during downstream processing of monoclonal antibodies from CHO cell cultures. Biotechnol Bioeng. 2019;116:1669\u201383. https:\/\/doi.org\/10.1002\/bit.26964.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR86","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/bit.25495","volume":"112","author":"M Mun","year":"2015","unstructured":"Mun M, Khoo S, Do MA, Dvornicky J, Trexler\u2010Schmidt M, Kao Y, et al. Air sparging for prevention of antibody disulfide bond reduction in harvested CHO cell culture fluid. Biotechnol Bioeng. 2015;112:734\u201342. https:\/\/doi.org\/10.1002\/bit.25495.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2009.04.009","volume":"144","author":"G Zhao","year":"2009","unstructured":"Zhao G, Dong X-Y, Sun Y. Ligands for mixed-mode protein chromatography: principles, characteristics and design. J Biotechnol. 2009;144:3\u201311. https:\/\/doi.org\/10.1016\/j.jbiotec.2009.04.009.","journal-title":"J Biotechnol"},{"key":"3456_CR88","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jchromb.2011.02.047","volume":"879","author":"M Toueille","year":"2011","unstructured":"Toueille M, Uzel A, Depoisier J-F, Gantier R. Designing new monoclonal antibody purification processes using mixed-mode chromatography sorbents. J Chromatogr B. 2011;879:836\u201343. https:\/\/doi.org\/10.1016\/j.jchromb.2011.02.047.","journal-title":"J Chromatogr B"},{"key":"3456_CR89","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/bit.26278","volume":"114","author":"MW Handlogten","year":"2017","unstructured":"Handlogten MW, Zhu M, Ahuja S. Glutathione and thioredoxin systems contribute to recombinant monoclonal antibody interchain disulfide bond reduction during bioprocessing. Biotechnol Bioeng. 2017;114:1469\u201377. https:\/\/doi.org\/10.1002\/bit.26278.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/abt\/tbad028","volume":"7","author":"S Tang","year":"2024","unstructured":"Tang S, Tao J, Li Y. Challenges and solutions for the downstream purification of therapeutic proteins. Antib Ther. 2024;7:1\u201312. https:\/\/doi.org\/10.1093\/abt\/tbad028.","journal-title":"Antib Ther"},{"key":"3456_CR91","unstructured":"Fann JC, O\u2019Mara BW, Smith LR. Methods of antibody production that minimize disulfide bond reduction. US11760777B2, 2018."},{"key":"3456_CR92","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1002\/bit.27867","volume":"118","author":"D Weber","year":"2021","unstructured":"Weber D, Sittig C, Hubbuch J. Impact of freeze\u2013thaw processes on monoclonal antibody platform process development. Biotechnol Bioeng. 2021;118:3914\u201325. https:\/\/doi.org\/10.1002\/bit.27867.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR93","doi-asserted-by":"publisher","first-page":"480","DOI":"10.4161\/mabs.2.5.12645","volume":"2","author":"HF Liu","year":"2010","unstructured":"Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. MAbs. 2010;2:480\u201399. https:\/\/doi.org\/10.4161\/mabs.2.5.12645.","journal-title":"MAbs"},{"key":"3456_CR94","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1002\/bit.28464","volume":"120","author":"H Shirataki","year":"2023","unstructured":"Shirataki H, Matsumoto Y, Konoike F, Yamamoto S. Viral clearance in end\u2010to\u2010end integrated continuous process for mAb purification: total flow\u2010through integrated polishing on two columns connected to virus filtration. Biotechnol Bioeng. 2023;120:2977\u201388. https:\/\/doi.org\/10.1002\/bit.28464.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR95","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jchromb.2006.10.033","volume":"848","author":"D Low","year":"2007","unstructured":"Low D, O\u2019Leary R, Pujar NS. Future of antibody purification. J Chromatogr B Biomed Sci Appl. 2007;848:48\u201363. https:\/\/doi.org\/10.1016\/j.jchromb.2006.10.033.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"3456_CR96","doi-asserted-by":"publisher","unstructured":"jafarzadehchehraghi E alsadat, Akbarzadehlaleh P, Shamsasenjan K. Purification technologies of monoclonal antibodies: chromatographic methods. Adv Pharm Bull 2025. https:\/\/doi.org\/10.34172\/apb.43967.","DOI":"10.34172\/apb.43967"},{"key":"3456_CR97","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/bit.26265","volume":"114","author":"WK Chung","year":"2017","unstructured":"Chung WK, Russell B, Yang Y, Handlogten M, Hudak S, Cao M, et al. Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability. Biotechnol Bioeng. 2017;114:1264\u201374. https:\/\/doi.org\/10.1002\/bit.26265.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR98","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/bit.28593","volume":"121","author":"A Sakaki","year":"2024","unstructured":"Sakaki A, Namatame T, Nakaya M, Omasa T. Model\u2010based control system design to manage process parameters in mammalian cell culture for biopharmaceutical manufacturing. Biotechnol Bioeng. 2024;121:605\u201317. https:\/\/doi.org\/10.1002\/bit.28593.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR99","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1002\/bit.27808","volume":"118","author":"M Jones","year":"2021","unstructured":"Jones M, Palackal N, Wang F, Gaza\u2010Bulseco G, Hurkmans K, Zhao Y, et al. \u201cHigh\u2010risk\u201d host cell proteins (HCPs): a multi\u2010company collaborative view. Biotechnol Bioeng. 2021;118:2870\u201385. https:\/\/doi.org\/10.1002\/bit.27808.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2022.106155","volume":"199","author":"W Lu","year":"2022","unstructured":"Lu W, Zhang Z, Zhang S, Zhang T, Wan Y, Li Y. Screening of six cation exchange resins for high binding capacity, monomer purity and step yield: a case study. Protein Expr Purif. 2022;199:106155. https:\/\/doi.org\/10.1016\/j.pep.2022.106155.","journal-title":"Protein Expr Purif"},{"key":"3456_CR101","unstructured":"Lenhoff AM, Herman CE. Control of Host Cell Proteins in Monoclonal-Antibody Bioprocessing: Using Proteomic Analysis To Understand Impurity Clearance and Persistence During Purification.\u00a02023.\u00a0https:\/\/www.BioprocessintlCom\/Separation-Purification\/Control-of-Host-Cell-Proteins-in-Monoclonal-Antibody-Bioprocessing-Using-Proteomic-Analysis-to-Understand-Impurity-Clearance-and-Persistence-during-Purification. Accessed Mar 2026."},{"key":"3456_CR102","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/bit.21044","volume":"96","author":"S Ghose","year":"2007","unstructured":"Ghose S, Hubbard B, Cramer SM. Binding capacity differences for antibodies and Fc\u2010fusion proteins on Protein A chromatographic materials. Biotechnol Bioeng. 2007;96:768\u201379. https:\/\/doi.org\/10.1002\/bit.21044.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR103","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.tibtech.2010.02.001","volume":"28","author":"AA Shukla","year":"2010","unstructured":"Shukla AA, Th\u00f6mmes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010;28:253\u201361. https:\/\/doi.org\/10.1016\/j.tibtech.2010.02.001.","journal-title":"Trends Biotechnol"},{"key":"3456_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2732","author":"H Luo","year":"2019","unstructured":"Luo H, Tie L, Cao M, Hunter AK, Pabst TM, Du J, et al. Cathepsin L causes proteolytic cleavage of Chinese\u2010Hamster\u2010Ovary cell expressed proteins during processing and storage: identification, characterization, and mitigation. Biotechnol Prog. 2019. https:\/\/doi.org\/10.1002\/btpr.2732.","journal-title":"Biotechnol Prog"},{"key":"3456_CR105","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/bit.28846","volume":"122","author":"MM Goodarzi","year":"2025","unstructured":"Goodarzi MM, Jalalirad R. Clear insight into complex multimodal resins and impurities to overcome recombinant protein purification challenges: a review. Biotechnol Bioeng. 2025;122:5\u201329. https:\/\/doi.org\/10.1002\/bit.28846.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.slast.2025.100351","volume":"35","author":"M Sajed","year":"2025","unstructured":"Sajed M, Khan Z, Ashraf MU, Iftikhar H, Rahat TB, Falak S, et al. Single-step purification and formulation of antibody-drug conjugates using a miniaturized tangential flow filtration system. SLAS Technol. 2025;35:100351. https:\/\/doi.org\/10.1016\/j.slast.2025.100351.","journal-title":"SLAS Technol"},{"key":"3456_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/antib9020016","volume":"9","author":"Y Matsuda","year":"2020","unstructured":"Matsuda Y, Leung M, Okuzumi T, Mendelsohn B. A purification strategy utilizing hydrophobic interaction chromatography to obtain homogeneous species from a site-specific antibody drug conjugate produced by AJICAP\u2122 First Generation. Antibodies. 2020;9:16. https:\/\/doi.org\/10.3390\/antib9020016.","journal-title":"Antibodies"},{"key":"3456_CR108","doi-asserted-by":"publisher","first-page":"26411","DOI":"10.1021\/acs.analchem.5c03553","volume":"97","author":"L Cadang","year":"2025","unstructured":"Cadang L, Li S, Wang J, Stumpf A, Kempen T, Dai L, et al. Real-time bioconjugation reaction monitoring of antibody\u2013drug conjugates with multiattribute high-throughput hydrophobic interaction chromatography. Anal Chem. 2025;97:26411\u20138. https:\/\/doi.org\/10.1021\/acs.analchem.5c03553.","journal-title":"Anal Chem"},{"key":"3456_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2025.465916","volume":"1750","author":"T Hahn","year":"2025","unstructured":"Hahn T, Lyu F, Graf P, Richter S, Gandarilla J, Clyne D, et al. Model-based analysis of a hydrophobic interaction chromatography for antibody-drug conjugate purification. J Chromatogr A. 2025;1750:465916. https:\/\/doi.org\/10.1016\/j.chroma.2025.465916.","journal-title":"J Chromatogr A"},{"key":"3456_CR110","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1021\/bc400574z","volume":"25","author":"P Dennler","year":"2014","unstructured":"Dennler P, Chiotellis A, Fischer E, Br\u00e9geon D, Belmant C, Gauthier L, et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody\u2013drug conjugates. Bioconjug Chem. 2014;25:569\u201378. https:\/\/doi.org\/10.1021\/bc400574z.","journal-title":"Bioconjug Chem"},{"key":"3456_CR111","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/bc400490z","volume":"25","author":"ES Zimmerman","year":"2014","unstructured":"Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, et al. Production of site-specific antibody\u2013drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem. 2014;25:351\u201361. https:\/\/doi.org\/10.1021\/bc400490z.","journal-title":"Bioconjug Chem"},{"key":"3456_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17020194","volume":"17","author":"H Yao","year":"2016","unstructured":"Yao H, Jiang F, Lu A, Zhang G. Methods to design and synthesize antibody-drug conjugates (ADCs). Int J Mol Sci. 2016;17:194. https:\/\/doi.org\/10.3390\/ijms17020194.","journal-title":"Int J Mol Sci"},{"key":"3456_CR113","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/acs.bioconjchem.4c00084","volume":"35","author":"T Luu","year":"2024","unstructured":"Luu T, Gristwood K, Knight JC, J\u00f6rg M. Click chemistry: reaction rates and their suitability for biomedical applications. Bioconjug Chem. 2024;35:715\u201331. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00084.","journal-title":"Bioconjug Chem"},{"key":"3456_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500132","author":"T Wharton","year":"2025","unstructured":"Wharton T, Spring DR. Methods for the generation of single\u2010payload antibody\u2010drug conjugates. ChemMedChem. 2025. https:\/\/doi.org\/10.1002\/cmdc.202500132.","journal-title":"ChemMedChem"},{"key":"3456_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, et al. Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18:51. https:\/\/doi.org\/10.1186\/s13045-025-01704-3.","journal-title":"J Hematol Oncol"},{"key":"3456_CR116","unstructured":"Chen T, Zhang K, Gruenhagen J, Medley C. Hydrophobic Interaction Chromatography for Antibody Drug Conjugate Drug Distribution Analysis.\u00a02015.\u00a0https:\/\/www.AmericanpharmaceuticalreviewCom\/Featured-Articles\/177927-Hydrophobic-Interaction-Chromatography-for-Antibody-Drug-Conjugate-Drug-Distribution-Analysis\/. Accessed Mar 2026."},{"key":"3456_CR117","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jbiotec.2025.02.007","volume":"401","author":"S-H Han","year":"2025","unstructured":"Han S-H, Park S-Y, Cha H-M, Lee K-B, Lim J-H, Lee D-Y. A robust scale-down model development and process characterization for monoclonal antibody biomanufacturing using multivariate data analysis. J Biotechnol. 2025;401:11\u201320. https:\/\/doi.org\/10.1016\/j.jbiotec.2025.02.007.","journal-title":"J Biotechnol"},{"key":"3456_CR118","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1021\/acs.chemrev.2c00798","volume":"123","author":"CJ Taylor","year":"2023","unstructured":"Taylor CJ, Pomberger A, Felton KC, Grainger R, Barecka M, Chamberlain TW, et al. A brief introduction to chemical reaction optimization. Chem Rev. 2023;123:3089\u2013126. https:\/\/doi.org\/10.1021\/acs.chemrev.2c00798.","journal-title":"Chem Rev"},{"issue":"11","key":"3456_CR119","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1002\/slct.201903913","volume":"5","author":"J Miret","year":"2020","unstructured":"Miret J, Camps M, Farr\u00e0s M, Rom\u00e1n R, Erb S, Cianferani S, Casablancas A, Cair\u00f3 JJ. Insight on the impact of the reduction step on the site-directed conjugation of an anti-HER2 cysteine-engineered antibody. ChemistrySelect. 2020;5(11):3187\u201390. https:\/\/doi.org\/10.1002\/slct.201903913. Accessed Mar 2026.","journal-title":"ChemistrySelect"},{"key":"3456_CR120","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jbiotec.2017.03.006","volume":"248","author":"X Zhong","year":"2017","unstructured":"Zhong X, He T, Prashad AS, Wang W, Cohen J, Ferguson D, Tam AS, Sousa E, Lin L, Tchistiakova L, Gatto S. Mechanistic understanding of the cysteine capping modifications of antibodies enables selective chemical engineering in live mammalian cells. Journal of biotechnology. 2017;248:48\u201358. https:\/\/doi.org\/10.1016\/j.jbiotec.2017.03.006.","journal-title":"Journal of biotechnology"},{"key":"3456_CR121","unstructured":"Hunter AK, Fulton A, Pabst TM, Savery J. Clearance of Persistent Small-Molecule Impurities: Alternative Strategies.\u00a02016.\u00a0https:\/\/www.BioprocessintlCom\/Bioanalytical-Methods\/Clearance-of-Persistent-Small-Molecule-Impurities-Alternative-Strategies"},{"key":"3456_CR122","doi-asserted-by":"publisher","first-page":"38126","DOI":"10.1039\/D1RA07028B","volume":"11","author":"A Adhikari","year":"2021","unstructured":"Adhikari A, Bhattarai BR, Aryal A, Thapa N, Kc P, Adhikari A, et al. Reprogramming natural proteins using unnatural amino acids. RSC Adv. 2021;11:38126\u201345. https:\/\/doi.org\/10.1039\/D1RA07028B.","journal-title":"RSC Adv"},{"key":"3456_CR123","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1039\/D4MD00637B","volume":"16","author":"Q Yang","year":"2025","unstructured":"Yang Q, Liu Y. Technical, preclinical, and clinical developments of Fc-glycan-specific antibody\u2013drug conjugates. RSC Med Chem. 2025;16:50\u201362. https:\/\/doi.org\/10.1039\/D4MD00637B.","journal-title":"RSC Med Chem"},{"key":"3456_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2020.113615","volume":"595","author":"H Schneider","year":"2020","unstructured":"Schneider H, Deweid L, Avrutina O, Kolmar H. Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates. Anal Biochem. 2020;595:113615. https:\/\/doi.org\/10.1016\/j.ab.2020.113615.","journal-title":"Anal Biochem"},{"key":"3456_CR125","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1021\/acs.bioconjchem.1c00314","volume":"32","author":"C Ou","year":"2021","unstructured":"Ou C, Li C, Zhang R, Yang Q, Zong G, Dai Y, et al. One-pot conversion of free sialoglycans to functionalized glycan oxazolines and efficient synthesis of homogeneous antibody\u2013drug conjugates through site-specific chemoenzymatic glycan remodeling. Bioconjug Chem. 2021;32:1888\u201397. https:\/\/doi.org\/10.1021\/acs.bioconjchem.1c00314.","journal-title":"Bioconjug Chem"},{"key":"3456_CR126","doi-asserted-by":"publisher","first-page":"8170","DOI":"10.1021\/acs.analchem.0c00282","volume":"92","author":"BL Duivelshof","year":"2020","unstructured":"Duivelshof BL, Desligni\u00e8re E, Hernandez-Alba O, Ehkirch A, Toftevall H, Sj\u00f6gren J, et al. Glycan-mediated technology for obtaining homogeneous site-specific conjugated antibody\u2013drug conjugates: synthesis and analytical characterization by using complementary middle-up LC\/HRMS analysis. Anal Chem. 2020;92:8170\u20137. https:\/\/doi.org\/10.1021\/acs.analchem.0c00282.","journal-title":"Anal Chem"},{"key":"3456_CR127","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.3c00048","author":"C Tang","year":"2023","unstructured":"Tang C, Zeng Y, Zhang J, Zheng X, Tang F, Yao X, et al. One-pot assembly of dual-site-specific antibody-drug conjugates via glycan remodeling and affinity-directed traceless conjugation. Bioconjug Chem. 2023. https:\/\/doi.org\/10.1021\/acs.bioconjchem.3c00048.","journal-title":"Bioconjug Chem"},{"key":"3456_CR128","unstructured":"Yu Z, Li X, Lan M, Mao X. One-pot process for preparing intermediate of antibody-drug conjugate, 2020."},{"key":"3456_CR129","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jbiotec.2019.09.013","volume":"306","author":"S Andris","year":"2019","unstructured":"Andris S, Seidel J, Hubbuch J. Kinetic reaction modeling for antibody-drug conjugate process development. J Biotechnol. 2019;306:71\u201380. https:\/\/doi.org\/10.1016\/j.jbiotec.2019.09.013.","journal-title":"J Biotechnol"},{"key":"3456_CR130","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jbiotec.2018.10.003","volume":"288","author":"S Andris","year":"2018","unstructured":"Andris S, R\u00fcdt M, Rogalla J, Wendeler M, Hubbuch J. Monitoring of antibody-drug conjugation reactions with UV\/Vis spectroscopy. J Biotechnol. 2018;288:15\u201322. https:\/\/doi.org\/10.1016\/j.jbiotec.2018.10.003.","journal-title":"J Biotechnol"},{"key":"3456_CR131","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1002\/bit.27944","volume":"118","author":"H Hussain","year":"2021","unstructured":"Hussain H, Patel T, Ozanne AMS, Vito D, Ellis M, Hinchliffe M, et al. A comparative analysis of recombinant Fab and full\u2010length antibody production in Chinese hamster ovary cells. Biotechnol Bioeng. 2021;118:4815\u201328. https:\/\/doi.org\/10.1002\/bit.27944.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR132","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/B978-0-12-416039-2.00006-9","volume-title":"Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues","author":"RP Lyon","year":"2012","unstructured":"Lyon RP, Meyer DL, Setter JR, Senter PD. Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues. 2012. p. 123\u201338. https:\/\/doi.org\/10.1016\/B978-0-12-416039-2.00006-9."},{"key":"3456_CR133","unstructured":"O\u2019Mara B, Zhang C. Overcoming Challenges for Developing a Robust Downstream Process for Early Phase ADC Manufacturing Under Tight Timelines. Speed from Gene to Market, San Diego, CA: World ADC Conference; 2019."},{"key":"3456_CR134","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jssc.202100575","volume":"45","author":"Y Matsuda","year":"2022","unstructured":"Matsuda Y. Current approaches for the purification of antibody\u2013drug conjugates. J Sep Sci. 2022;45:27\u201337. https:\/\/doi.org\/10.1002\/jssc.202100575. Accessed Mar 2026.","journal-title":"J Sep Sci"},{"key":"3456_CR135","unstructured":"Alexander P, Weitzel K, Linderholm A, Haskins W, Ghone S, Chamow S. Manufacturing Challenges of Therapeutic Antibody\u2013Drug Conjugates.\u00a02023.\u00a0https:\/\/www.BioprocessintlCom\/Emerging-Therapeutics-Manufacturing\/Manufacturing-Challenges-of-Therapeutic-Antibody-Drug-Conjugates"},{"key":"3456_CR136","unstructured":"Center for Drug Evaluation NMPA. Technical Guideline for Antibody-Drug Conjugate Pharmaceutical Study and Evaluation.\u00a02024.\u00a0https:\/\/www.CcfdieOrg\/En\/Gzdt\/Webinfo\/2024\/12\/1732613151853611Htm"},{"key":"3456_CR137","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1016\/j.xphs.2023.09.007","volume":"112","author":"K Bechtold-Peters","year":"2023","unstructured":"Bechtold-Peters K, Ruggiero A, Vriezen N, Ihle N, Klein A, Morgan C, et al. CMC regulatory considerations for antibody-drug conjugates. J Pharm Sci. 2023;112:2965\u201380. https:\/\/doi.org\/10.1016\/j.xphs.2023.09.007.","journal-title":"J Pharm Sci"},{"key":"3456_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030552","volume":"10","author":"JC Cordova","year":"2021","unstructured":"Cordova JC, Sun S, Bos J, Thirumalairajan S, Ghone S, Hirai M, et al. Development of a single-step antibody\u2013drug conjugate purification process with membrane chromatography. J Clin Med. 2021;10:552. https:\/\/doi.org\/10.3390\/jcm10030552.","journal-title":"J Clin Med"},{"key":"3456_CR139","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.chroma.2018.01.039","volume":"1539","author":"A Goyon","year":"2018","unstructured":"Goyon A, Sciascera L, Clarke A, Guillarme D, Pell R. Extending the limits of size exclusion chromatography: simultaneous separation of free payloads and related species from antibody drug conjugates and their aggregates. J Chromatogr A. 2018;1539:19\u201329. https:\/\/doi.org\/10.1016\/j.chroma.2018.01.039.","journal-title":"J Chromatogr A"},{"key":"3456_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/ph13120462","volume":"13","author":"H Cahuzac","year":"2020","unstructured":"Cahuzac H, Devel L. Analytical methods for the detection and quantification of ADCs in biological matrices. Pharmaceuticals. 2020;13:462. https:\/\/doi.org\/10.3390\/ph13120462. Accessed Mar 2026.","journal-title":"Pharmaceuticals"},{"key":"3456_CR141","doi-asserted-by":"publisher","first-page":"28132","DOI":"10.1021\/acs.analchem.5c05683","volume":"97","author":"K Zhou","year":"2025","unstructured":"Zhou K, Xia Y. Bottom\u2013up protein analysis workflow for simultaneous characterization of payloads, disulfide bonds, and free thiols in antibody\u2013drug conjugates. Anal Chem. 2025;97:28132\u20138. https:\/\/doi.org\/10.1021\/acs.analchem.5c05683.","journal-title":"Anal Chem"},{"key":"3456_CR142","unstructured":"International Council for Harmonization (ICH). Q3C (R6): Impurities: Guideline for Residual Solvents.\u00a02016.\u00a0https:\/\/www.DatabaseIchOrg\/Sites\/Default\/Files\/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0Pdf"},{"key":"3456_CR143","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/antib2030452","volume":"2","author":"S Goswami","year":"2013","unstructured":"Goswami S, Wang W, Arakawa T, Ohtake S. Developments and challenges for mAb-based therapeutics. Antibodies. 2013;2:452\u2013500. https:\/\/doi.org\/10.3390\/antib2030452.","journal-title":"Antibodies"},{"key":"3456_CR144","doi-asserted-by":"publisher","unstructured":"Herbert N, Das J, Patel P. Validating Protein Concentration of Antibody-Drug Conjugates with the CTechTM SoloVPE\u00ae System. ADC Review \/ Journal of Antibody-Drug Conjugates 2022. https:\/\/doi.org\/10.14229\/jadc.2022.08.31.001.","DOI":"10.14229\/jadc.2022.08.31.001"},{"key":"3456_CR145","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/bit.28397","volume":"120","author":"H Schwarz","year":"2023","unstructured":"Schwarz H, Lee K, Castan A, Chotteau V. Optimization of medium with perfusion microbioreactors for high density CHO cell cultures at very low renewal rate aided by design of experiments. Biotechnol Bioeng. 2023;120:2523\u201341. https:\/\/doi.org\/10.1002\/bit.28397.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR146","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/btpr.2277","volume":"32","author":"N Magarian","year":"2016","unstructured":"Magarian N, Lee K, Nagpal K, Skidmore K, Mahajan E. Clearance of extractables and leachables from single\u2010use technologies via ultrafiltration\/diafiltration operations. Biotechnol Prog. 2016;32:718\u201324. https:\/\/doi.org\/10.1002\/btpr.2277.","journal-title":"Biotechnol Prog"},{"key":"3456_CR147","unstructured":"Jagschies G, Lindskog Eva, \u0141\u0105cki Karol, Galliher Parrish. Biopharmaceutical processing\u202f: development, design, and implementation of manufacturing processes. Elsevier; 2018."},{"key":"3456_CR148","unstructured":"Meyer D, Sun M. ACTIVATED Carbon filtration for purification of benzodiazepine ADCs. WO2014143622A1, 2014."},{"key":"3456_CR149","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1021\/bc400217g","volume":"24","author":"SC Jeffrey","year":"2013","unstructured":"Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, et al. A potent anti-CD70 antibody\u2013drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013;24:1256\u201363. https:\/\/doi.org\/10.1021\/bc400217g.","journal-title":"Bioconjug Chem"},{"key":"3456_CR150","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1021\/acs.oprd.3c00137","volume":"27","author":"L Fernandez-Cerezo","year":"2023","unstructured":"Fernandez-Cerezo L, Holstein M, Thirumalairajan S, Romanini D, Kos P, Raglione T, et al. Strategies for UF\/DF-based impurity removal in the post-conjugation purification of antibody\u2013drug conjugates. Org Process Res Dev. 2023;27:1258\u201368. https:\/\/doi.org\/10.1021\/acs.oprd.3c00137.","journal-title":"Org Process Res Dev"},{"key":"3456_CR151","doi-asserted-by":"publisher","unstructured":"Ha B, Guly\u00e1s Z. Methodology for assessing Repligen ProStream\u00ae and HyStream\u00ae Tangential Flow Filtration Cassettes in an Antibody-Drug-Conjugate Process. ADC Review \/ J Antibody-Drug Conjugates 2024. https:\/\/doi.org\/10.14229\/jadc.2024.11.08.001.","DOI":"10.14229\/jadc.2024.11.08.001"},{"key":"3456_CR152","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.3c00040","author":"T Fujii","year":"2023","unstructured":"Fujii T, Matsuda Y, Seki T, Shikida N, Iwai Y, Ooba Y, et al. AJICAP second generation: improved chemical site-specific conjugation technology for antibody-drug conjugate production. Bioconjug Chem. 2023. https:\/\/doi.org\/10.1021\/acs.bioconjchem.3c00040.","journal-title":"Bioconjug Chem"},{"key":"3456_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2026.466711","volume":"1768","author":"D Kumar","year":"2026","unstructured":"Kumar D, Trivedi N. Multi-attribute methods in antibody-drug conjugate characterization and quality control: opportunities, challenges, and regulatory outlook. J Chromatogr A. 2026;1768:466711. https:\/\/doi.org\/10.1016\/j.chroma.2026.466711.","journal-title":"J Chromatogr A"},{"key":"3456_CR154","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jpba.2016.08.019","volume":"131","author":"B Bobaly","year":"2016","unstructured":"Bobaly B, Beck A, Veuthey J-L, Guillarme D, Fekete S. Impact of organic modifier and temperature on protein denaturation in hydrophobic interaction chromatography. J Pharm Biomed Anal. 2016;131:124\u201332. https:\/\/doi.org\/10.1016\/j.jpba.2016.08.019.","journal-title":"J Pharm Biomed Anal"},{"key":"3456_CR155","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1389203718666171020103559","volume":"20","author":"V Halan","year":"2018","unstructured":"Halan V, Maity S, Bhambure R, Rathore AS. Multimodal chromatography for purification of biotherapeutics \u2013 a review. Curr Protein Pept Sci. 2018;20:4\u201313. https:\/\/doi.org\/10.2174\/1389203718666171020103559.","journal-title":"Curr Protein Pept Sci"},{"key":"3456_CR156","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c21-00258","volume":"69","author":"Y Matsuda","year":"2021","unstructured":"Matsuda Y, Mendelsohn BA. Recent advances in drug\u2013antibody ratio determination of antibody\u2013drug conjugates. Chem Pharm Bull (Tokyo). 2021;69:c21-00258. https:\/\/doi.org\/10.1248\/cpb.c21-00258.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"3456_CR157","doi-asserted-by":"publisher","first-page":"9698","DOI":"10.1021\/acs.analchem.9b01234","volume":"91","author":"PD Hutchins","year":"2019","unstructured":"Hutchins PD, Russell JD, Coon JJ. Accelerating lipidomic method development through in silico simulation. Anal Chem. 2019;91:9698\u2013706. https:\/\/doi.org\/10.1021\/acs.analchem.9b01234.","journal-title":"Anal Chem"},{"key":"3456_CR158","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpha.2020.05.008","volume":"10","author":"X Zhu","year":"2020","unstructured":"Zhu X, Huo S, Xue C, An B, Qu J. Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. J Pharm Anal. 2020;10:209\u201320. https:\/\/doi.org\/10.1016\/j.jpha.2020.05.008.","journal-title":"J Pharm Anal"},{"key":"3456_CR159","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/bc9002019","volume":"21","author":"L Ducry","year":"2010","unstructured":"Ducry L, Stump B. Antibody\u2212drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21:5\u201313. https:\/\/doi.org\/10.1021\/bc9002019.","journal-title":"Bioconjug Chem"},{"key":"3456_CR160","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/19420862.2017.1402995","volume":"10","author":"M Jo","year":"2018","unstructured":"Jo M, Kwon HS, Lee K-H, Lee JC, Jung ST. Engineered aglycosylated full-length IgG Fc variants exhibiting improved Fc\u03b3RIIIa binding and tumor cell clearance. MAbs. 2018;10:278\u201389. https:\/\/doi.org\/10.1080\/19420862.2017.1402995.","journal-title":"MAbs"},{"key":"3456_CR161","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1021\/acsptsci.3c00235","volume":"7","author":"H Chen","year":"2024","unstructured":"Chen H, Qiu D, Shi J, Wang N, Li M, Wu Y, et al. In-depth structure and function characterization of heterogeneous interchain cysteine-conjugated antibody\u2013drug conjugates. ACS Pharmacol Transl Sci. 2024;7:212\u201321. https:\/\/doi.org\/10.1021\/acsptsci.3c00235.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3456_CR162","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nbt.3274","volume":"33","author":"P Strop","year":"2015","unstructured":"Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol. 2015;33:694\u20136. https:\/\/doi.org\/10.1038\/nbt.3274.","journal-title":"Nat Biotechnol"},{"key":"3456_CR163","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","volume":"30","author":"B-Q Shen","year":"2012","unstructured":"Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30:184\u20139. https:\/\/doi.org\/10.1038\/nbt.2108.","journal-title":"Nat Biotechnol"},{"key":"3456_CR164","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/biot.201200018","volume":"8","author":"AL Tscheliessnig","year":"2013","unstructured":"Tscheliessnig AL, Konrath J, Bates R, Jungbauer A. Host cell protein analysis in therapeutic protein bioprocessing \u2013 methods and applications. Biotechnol J. 2013;8:655\u201370. https:\/\/doi.org\/10.1002\/biot.201200018.","journal-title":"Biotechnol J"},{"key":"3456_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2026.466966","volume":"1777","author":"E Wagner","year":"2026","unstructured":"Wagner E, Maurer J, Zanna L, Colas O, Humbert A, Guillarme D, et al. Comprehensive evaluation of the analytical toolbox for commercial cysteine-linked antibody-drug conjugates. J Chromatogr A. 2026;1777:466966. https:\/\/doi.org\/10.1016\/j.chroma.2026.466966.","journal-title":"J Chromatogr A"},{"key":"3456_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89145-3","volume":"15","author":"J Cai","year":"2025","unstructured":"Cai J, Li M-X, Lu S, Shen D, Xie W, Zhu J-J, et al. Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services. Sci Rep. 2025;15:4653. https:\/\/doi.org\/10.1038\/s41598-025-89145-3.","journal-title":"Sci Rep"},{"key":"3456_CR167","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1002\/bit.24584","volume":"109","author":"V Warikoo","year":"2012","unstructured":"Warikoo V, Godawat R, Brower K, Jain S, Cummings D, Simons E, et al. Integrated continuous production of recombinant therapeutic proteins. Biotechnol Bioeng. 2012;109:3018\u201329. https:\/\/doi.org\/10.1002\/bit.24584.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR168","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1002\/bit.28738","volume":"121","author":"A Jungbauer","year":"2024","unstructured":"Jungbauer A, Ferreira G, Butler M, D\u2019Costa S, Brower K, Rayat A, et al. Status and future developments for downstream processing of biological products. Biotechnol Bioeng. 2024;121:2524\u201341. https:\/\/doi.org\/10.1002\/bit.28738.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR169","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1903664","author":"O Khanal","year":"2021","unstructured":"Khanal O, Lenhoff AM. Developments and opportunities in continuous biopharmaceutical manufacturing. MAbs. 2021. https:\/\/doi.org\/10.1080\/19420862.2021.1903664.","journal-title":"MAbs"},{"key":"3456_CR170","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.chroma.2013.01.082","volume":"1284","author":"J Pollock","year":"2013","unstructured":"Pollock J, Bolton G, Coffman J, Ho SV, Bracewell DG, Farid SS. Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. J Chromatogr A. 2013;1284:17\u201327. https:\/\/doi.org\/10.1016\/j.chroma.2013.01.082.","journal-title":"J Chromatogr A"},{"key":"3456_CR171","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/bit.28641","volume":"121","author":"L Crowley","year":"2024","unstructured":"Crowley L, Cashen P, Noverraz M, Lobedann M, Nestola P. Reviewing the process intensification landscape through the introduction of a novel, multitiered classification for downstream processing. Biotechnol Bioeng. 2024;121:877\u201393. https:\/\/doi.org\/10.1002\/bit.28641.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR172","unstructured":"Yamaguchi T, Sakuratani K. Effective method for manufacturing antibody-drug conjugate, 2019. US20210283269A1"},{"key":"3456_CR173","doi-asserted-by":"publisher","unstructured":"Kateja N, Nitika, Dureja S, Rathore AS. Development of an integrated continuous PEGylation and purification Process for granulocyte colony stimulating factor. J Biotechnol 2020;322:79\u201389. https:\/\/doi.org\/10.1016\/j.jbiotec.2020.07.008.","DOI":"10.1016\/j.jbiotec.2020.07.008"},{"key":"3456_CR174","unstructured":"Rathore A, Prasad Nigam KD, Pathak M, Agarwal H, Sharma AK, Kateja N, et al. A coiled flow inverter reactor for continuous refolding of denatured recombinant proteins and other mixing operations. WO2016116947A1, 2016."},{"key":"3456_CR175","unstructured":"Denk R. The Challenge of cGMP in the Manufacturing of Antibody-drug Conjugates. ADC Review 2016."},{"key":"3456_CR176","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1021\/acs.oprd.3c00264","volume":"27","author":"S Nayak","year":"2023","unstructured":"Nayak S, Richter SM. Kinetic studies of the partial reduction and conjugation reactions in an antibody-drug conjugate (ADC) synthesis. Org Process Res Dev. 2023;27:2091\u20139. https:\/\/doi.org\/10.1021\/acs.oprd.3c00264.","journal-title":"Org Process Res Dev"},{"key":"3456_CR177","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1021\/acs.oprd.4c00226","volume":"28","author":"MH Emmert","year":"2024","unstructured":"Emmert MH, Bottecchia C, Barrientos RC, Feng Y, Holland-Moritz D, Hughes GJ, et al. \u201cBuild your own\u201d ADC mimics: Identification of nontoxic linker\/payload mimics for HIC-based DAR determination, high-throughput optimization, and continuous flow conjugation. Org Process Res Dev. 2024;28:3326\u201338. https:\/\/doi.org\/10.1021\/acs.oprd.4c00226.","journal-title":"Org Process Res Dev"},{"key":"3456_CR178","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1002\/bit.24901","volume":"110","author":"M Kr\u00e4ttli","year":"2013","unstructured":"Kr\u00e4ttli M, M\u00fcller\u2010Sp\u00e4th T, Morbidelli M. Multifraction separation in countercurrent chromatography (MCSGP). Biotechnol Bioeng. 2013;110:2436\u201344. https:\/\/doi.org\/10.1002\/bit.24901.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR179","doi-asserted-by":"publisher","first-page":"10764","DOI":"10.1021\/acs.iecr.1c01345","volume":"60","author":"TK Kim","year":"2021","unstructured":"Kim TK, Botti C, Angelo J, Xu X, Ghose S, Li ZJ, et al. Experimental design of the multicolumn countercurrent solvent gradient purification (MCSGP) unit for the separation of PEGylated proteins. Ind Eng Chem Res. 2021;60:10764\u201376. https:\/\/doi.org\/10.1021\/acs.iecr.1c01345.","journal-title":"Ind Eng Chem Res"},{"key":"3456_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2023.464292","volume":"1707","author":"S-Y Jing","year":"2023","unstructured":"Jing S-Y, Shi C, Gao D, Wang H-B, Yao S-J, Lin D-Q. Improved process design for monoclonal antibody charge variants separation with multicolumn counter-current solvent gradient purification. J Chromatogr A. 2023;1707:464292. https:\/\/doi.org\/10.1016\/j.chroma.2023.464292.","journal-title":"J Chromatogr A"},{"key":"3456_CR181","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/B978-0-443-15369-3.00029-8","volume-title":"Ion-Exchange Chromatography and Related Techniques","author":"Y-C Chen","year":"2024","unstructured":"Chen Y-C, Mao R-Q, Yao S-J, Lin D-Q. Continuous ion-exchange chromatography for protein polishing and enrichment. In: Ion-Exchange Chromatography and Related Techniques. Elsevier; 2024. p. 535\u201352. https:\/\/doi.org\/10.1016\/B978-0-443-15369-3.00029-8."},{"key":"3456_CR182","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/bit.28537","volume":"121","author":"F Konoike","year":"2024","unstructured":"Konoike F, Taniguchi M, Yamamoto S. Integrated continuous downstream process of monoclonal antibody developed by converting the batch platform process based on the process characterization. Biotechnol Bioeng. 2024;121:2269\u201377. https:\/\/doi.org\/10.1002\/bit.28537.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR183","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/bit.28586","volume":"121","author":"T Kruse","year":"2024","unstructured":"Kruse T, Austerjost J, Lemke J, Krasov Y, Popov V, Pollard D, et al. Advanced control strategies for continuous capture of monoclonal antibodies based upon biolayer interferometry. Biotechnol Bioeng. 2024;121:771\u201383. https:\/\/doi.org\/10.1002\/bit.28586.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR184","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/btpr.212","volume":"25","author":"AS Rathore","year":"2009","unstructured":"Rathore AS, Li X, Bartkowski W, Sharma A, Lu Y. Case study and application of process analytical technology (PAT) towards bioprocessing: use of tryptophan fluorescence as at\u2010line tool for making pooling decisions for process chromatography. Biotechnol Prog. 2009;25:1433\u20139. https:\/\/doi.org\/10.1002\/btpr.212.","journal-title":"Biotechnol Prog"},{"key":"3456_CR185","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1002\/bit.28466","volume":"120","author":"MN S\u00e3o Pedro","year":"2023","unstructured":"S\u00e3o Pedro MN, Isaksson M, Gomis\u2010Fons J, Eppink MHM, Nilsson B, Ottens M. Real\u2010time detection of mAb aggregates in an integrated downstream process. Biotechnol Bioeng. 2023;120:2989\u20133000. https:\/\/doi.org\/10.1002\/bit.28466.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08151-2","volume":"7","author":"Y Tang","year":"2017","unstructured":"Tang Y, Tang F, Yang Y, Zhao L, Zhou H, Dong J, et al. Real-time analysis on drug-antibody ratio of antibody-drug conjugates for synthesis, process optimization, and quality control. Sci Rep. 2017;7:7763. https:\/\/doi.org\/10.1038\/s41598-017-08151-2.","journal-title":"Sci Rep"},{"key":"3456_CR187","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/bit.28899","volume":"122","author":"JT Weggen","year":"2025","unstructured":"Weggen JT, Gonz\u00e1lez P, Hui K, Bean R, Wendeler M, Hubbuch J. Kinetic modeling of the antibody disulfide bond reduction reaction with integrated prediction of the drug load profile for cysteine\u2010conjugated ADCs. Biotechnol Bioeng. 2025;122:579\u201393. https:\/\/doi.org\/10.1002\/bit.28899.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR188","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3236","author":"RP Bhangale","year":"2022","unstructured":"Bhangale RP, Ye R, Lindsey TB, Wolfe LS. Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals. Biotechnol Prog. 2022. https:\/\/doi.org\/10.1002\/btpr.3236.","journal-title":"Biotechnol Prog"},{"key":"3456_CR189","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2116\/analsci.20P424","volume":"37","author":"Y Matsuda","year":"2021","unstructured":"Matsuda Y, Leung M, Tawfiq Z, Fujii T, Mendelsohn BA. In-situ reverse phased HPLC analysis of intact antibody-drug conjugates. Anal Sci. 2021;37:1171\u20136. https:\/\/doi.org\/10.2116\/analsci.20P424.","journal-title":"Anal Sci"},{"key":"3456_CR190","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/bit.28235","volume":"120","author":"AS Rathore","year":"2023","unstructured":"Rathore AS, Thakur G, Kateja N. Continuous integrated manufacturing for biopharmaceuticals: a new paradigm or an empty promise? Biotechnol Bioeng. 2023;120:333\u201351. https:\/\/doi.org\/10.1002\/bit.28235.","journal-title":"Biotechnol Bioeng"},{"key":"3456_CR191","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.chroma.2016.05.086","volume":"1455","author":"C Wang","year":"2016","unstructured":"Wang C, Chen S, Caceres-Cortes J, Huang RY-C, Tymiak AA, Zhang Y. Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. J Chromatogr A. 2016;1455:133\u20139. https:\/\/doi.org\/10.1016\/j.chroma.2016.05.086.","journal-title":"J Chromatogr A"},{"key":"3456_CR192","doi-asserted-by":"publisher","unstructured":"Nixon M, Fran\u00e7ois B. Validation of ADC Platform for Protein Concentration and the Drug-Antibody Ratio (DAR) using Variable Pathlength Technology. ADC Review \/ Journal of Antibody-Drug Conjugates 2023. https:\/\/doi.org\/10.14229\/jadc.2023.12.05.001.","DOI":"10.14229\/jadc.2023.12.05.001"},{"key":"3456_CR193","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.aca.2019.07.007","volume":"1081","author":"C Zhang","year":"2019","unstructured":"Zhang C, Springall JS, Wang X, Barman I. Rapid, quantitative determination of aggregation and particle formation for antibody drug conjugate therapeutics with label-free Raman spectroscopy. Anal Chim Acta. 2019;1081:138\u201345. https:\/\/doi.org\/10.1016\/j.aca.2019.07.007. Accessed Mar 2026.","journal-title":"Anal Chim Acta"},{"key":"3456_CR194","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00216-019-02318-8","volume":"412","author":"L Rolinger","year":"2020","unstructured":"Rolinger L, R\u00fcdt M, Diehm J, Chow-Hubbertz J, Heitmann M, Schleper S, et al. Multi-attribute PAT for UF\/DF of proteins\u2014monitoring concentration, particle sizes, and buffer exchange. Anal Bioanal Chem. 2020;412:2123\u201336. https:\/\/doi.org\/10.1007\/s00216-019-02318-8.","journal-title":"Anal Bioanal Chem"},{"key":"3456_CR195","unstructured":"Piazza M. Fast-Tracking ADC Development and Commercialization.\u00a02019.\u00a0https:\/\/www.PharmasalmanacCom\/Articles\/Fast-Tracking-Adc-Development-and-Commercialization"},{"key":"3456_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2020.113909","volume":"609","author":"M Zarrineh","year":"2020","unstructured":"Zarrineh M, Mashhadi IS, Farhadpour M, Ghassempour A. Mechanism of antibodies purification by Protein A. Anal Biochem. 2020;609:113909. https:\/\/doi.org\/10.1016\/j.ab.2020.113909.","journal-title":"Anal Biochem"},{"key":"3456_CR197","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3425","author":"K Brower","year":"2024","unstructured":"Brower K, Wiltberger K, Berdugo C, Bosley A, Goodrich E, Pferdeort V, et al. Process development and characterization for integrated continuous bioprocesses\u2014highlights from N\u2010mAb. Biotechnol Prog. 2024. https:\/\/doi.org\/10.1002\/btpr.3425.","journal-title":"Biotechnol Prog"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03456-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03456-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03456-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:05:11Z","timestamp":1790280311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03456-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":197,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3456"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03456-w","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AI was used for language guidance (ChatGPT) and grammar editing (Grammarly). All scientific content is author-developed from references. No AI-generated images were used.","order":1,"name":"Ethics","label":"A.I. Disclosure Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"233"}}